Osiris Therapeutics Reports CMS Decides to Package Reimbursement for Products Used in Advanced Wound Care with the Related Surgical Procedure into Two-Tier System

Osiris Therapeutics

announced today that, on November 27, 2013, the Centers for Medicare and Medicaid Services (CMS) released their proposed ruling for the reimbursement of skin substitutes in the hospital outpatient setting. CMS decided to package the reimbursement for products used in advanced wound care with the related surgical procedure into a two-tier system. The proposed ruling means that the current payment methodology for Grafix® will not immediately be impacted by the changes described in the proposed ruling. Grafix will maintain its current transitional pass-through status and that